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Abstract Several years ago, we described Myc as ‘‘the
oncogene from hell’’, since evidence had just emerged that
Myc, aside from being responsible for cell-cycle progres-
sion and tumor expansion, was also able to induce genomic
instability in culture, wreaking havoc in tumor cells and
accelerating tumor progression (Soucek and Evan, Cancer
Cell 1:406–408, 2002; Vafa et al., Mol Cell 9:1031–1044,
2002). In this review, we discuss recent publications that
expand Myc’s evil armory to include coordination of the
crosstalk between tumor and microenvironment. Indeed,
endogenous Myc, acting as a client for upstream oncogenic
lesions, instructs the tumor stroma, engages a complex
inﬂammatory response and induces angiogenesis, thus
allowing the tumor to thrive. This is highly topical in light
of the fact that Hanahan and Weinberg have recently
redeﬁned the hallmarks of cancer and pointed out that
genomic instability and inﬂammation are essential for both
their acquisition and development (Hanahan and Weinberg,
Cell 144:646–674, 2011). Myc, it seems, is behind it all.
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VEGF Vascular endothelial growth factor
IL-1b Interleukin-1b
Hif1a Hypoxia-inducible transcription factor 1 alpha
Bcl-xl B-cell lymphoma-extra large
RIP Rat insulin promoter 1
SV40 Simian virus 40
Introduction
Myc is a highly pleiotropic transcription factor known to
control proliferation, metabolism, differentiation, and
apoptosis [4–6]. Normally its expression is tightly regu-
lated. In human cancer, however, Myc’s deregulated
expression is often observed and is considered a poor
prognostic factor [7–10]. Myc is evolutionarily conserved
as an integrator of extracellular and intracellular signals
leading to cell growth and division, tissue regeneration, and
remodeling [11]. Indeed, during development, myc family
gene expression is highest during embryonic stages and is
downregulated in mature organs, due to cell growth arrest
and differentiation [12].
Genetic knockout of the c-myc gene leads to embryonic
lethality and, as elegantly shown by Baudino et al. [13],
this is partially due to defects in vasculogenesis caused by
the lack of proper Vascular Endothelial Growth Factor
(VEGF) signaling [13]. In the same study, a role in murine
embryonic stem cells and derived teratomas was attributed
to Myc in the regulation of other proteins strictly involved
in angiogenesis, such as thrombospondin-1 and angio-
poietin-1 and -2, providing the ﬁrst evidence to show Myc
as a master regulator of vascular remodeling [13]. Myc’s
role in embryonic development has recently been deﬁned
more precisely by the use of cell lineage speciﬁc deletion
[14]: embryos lacking c-myc in both endothelial and
hematopoietic compartments phenocopied those lacking
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123c-myc in the entire embryo, as a consequence of defective
hematopoiesis and vasculogenesis. Surprisingly though,
c-myc deletion in endothelial cells alone did not prevent
endothelial cell proliferation and vasculogenesis. Thus, it is
c-myc-mediated hematopoiesis that is critical for blood
vessel formation during mammalian development [14].
Further evidence for the regulation of VEGF and angio-
genesis by Myc was provided by Mezquita and colleagues
[15], who demonstrated that a human B-cell line increases
VEGF production tenfold upon Myc overexpression, due to
increased initiation of VEGF mRNA translation. Ngo et al.
[16] conﬁrmed in vivo Myc’s down-modulation of
thrombospondin-1 by making use of Myc-transformed Rat-
1A ﬁbroblasts that form vascular tumors in immunocom-
promised mice. Finally, Dews and colleagues [17]
suggested that thrombospondin-1 is downregulated by Myc
through induction of the miR-17-92 microRNA cluster,
using p53-null mouse colonocytes transformed in vitro by
low-grade overexpression of activated K-Ras and Myc, and
engrafted into the cecal wall of syngeneic mice. Collec-
tively, these results show that Myc efﬁciently modulates in
vivo various potent factors implicated in neoangiogenesis.
Another giant leap forward in understanding Myc’s role
as instructor of the tumor microenvironment was made
using mouse models of Myc-induced tumorigenesis. In
particular, the use of reversibly switchable models that
allowed synchronous activation or deactivation of Myc
also permitted deconvolution of the cause-and-effect pro-
cesses consequent to activation of the oncogene in vivo.
One of these models is the pInsMycER
Tam;RIP-BclXL
model of pancreatic b-cell tumorigenesis, in which
expression of a MycER fusion protein is spatially con-
trolled by the tissue-speciﬁc insulin promoter (pIns) and
temporally regulated by the administration of 4-hydroxy-
tamoxifen [18]. Apoptosis is prevented by co-expression of
B-cell lymphoma-extra large (Bcl-xl) driven from the Rat
insulin promoter 1 (RIP). In this model, Shchors et al.
demonstrated that acute Myc activation in b-cells triggers
the release of factors that induce proliferation of adjacent
endothelial cells, and their subsequent formation of leaky
and complex vessels [19]. This process is mediated by the
release of interleukin-1b (IL-1b)b yb-cells, which leads to
mobilization of VEGF-A bound to the extracellular matrix,
presumably through the action of extracellular proteases
[19, 20].
In the same mouse model, we showed that Myc alone
causes a complex inﬂammatory response, leading to the
recruitment of various inﬂammatory cells. Among those,
mast cells are absolutely required for tumor expansion and
sustained proliferation of endothelial cells within the tumor
[21]. We also showed that inhibitors of mast cell function
rapidly triggered hypoxia and cell death in tumors and
vessels, which suggests that there are Myc effectors in the
tumor stroma, offering new therapeutic opportunities [21].
These data underscore the essential role of the activation of
inﬂammatory pathways for Myc’s oncogenic activity and,
together with the previous work by Shchors et al. [19],
demonstrate that Myc can directly instruct tissue remod-
eling, angiogenesis and inﬂammation.
Other studies have suggested the intriguing possibility
of bi-directional crosstalk between Myc-driven tumors and
their microenvironment. Giuriato et al. [22] and Rakhra
et al. [23] showed that, in a conditional mouse model for
Myc-induced tumorigenesis in hematopoietic cells, com-
plete tumor regression, cellular senescence and shutdown
of angiogenesis upon Myc inactivation can be achieved
only through persistent expression of thrombospondin-1
[22] and in the presence of CD4(
?) T cells [23].
Furthermore, hypoxia and other environmental stresses
can affect c-Myc expression itself. For instance, low oxy-
gen supply leads to stabilization of hypoxia-inducible
transcription factor 1 alpha (Hif1a), whose transcriptional
activity both antagonizes and cooperates with Myc [24],
while low oxygen and glucose deﬁciency can destabilize
Myc [25].
Yet, for a long time, Myc’s interaction with the
microenvironment was thought to be a prerogative of
overexpressed and not physiological levels of Myc. More
recently, we made use of a dominant-negative form of
Myc, termed Omomyc, to assess the requirement for
Myc activity in tumorigenesis. More speciﬁcally, we
decided to study b-cell insulinomas arising in Rip-Tag2
mice that express Simian virus 40 (SV40) T/t antigens,
the ‘workhorse’ for tumor microenvironment and angio-
genic switch studies [26, 27]. We crossed these mice
with the TREOmomyc;CMVrtTA strain, thus enabling
controlled expression of Omomyc in most mouse organs
[28]. This dominant-negative mutant interferes with
Myc’s transactivation activity [29], and we sought to
establish the extent to which tumor angiogenesis is
dependent upon endogenous Myc. Strikingly, given the
enormous transforming potential of T/t antigens, tumor
expansion was completely prevented by Myc inhibition,
and furthermore, tumors collapsed after induced expres-
sion of Omomyc [30]. Notably, at no stage of tumor
evolution was Myc overexpressed, suggesting it functions
simply—but critically—as a client for upstream SV40
oncoproteins. Similarly, in most human cancers, Myc
does not appear to be mutated itself, but more typically
is induced by altered signal transduction [31]. Our results
show that, even in cases where it is not upregulated,
Myc still has a crucial part to play in tumorigenesis.
Indeed, inhibition of endogenous—neither mutated nor
overexpressed—Myc has a huge impact on the tumor
stroma: it impairs VEGF signaling, causes disappearance
of inﬁltrating inﬂammatory cells and leads to vasculature
932 J. R. Whitﬁeld, L. Soucek
123collapse, all events that precede actual tumor regression
[30]. Importantly, this holds true even when Myc is
inhibited exclusively in tumor cells and not the micro-
environment [30], showing that it is Myc in the tumor
cells that directs changes in the tumor stroma.
This is particularly intriguing when considered together
with recent data from Pello et al. [32], which deﬁne a clear
role for Myc in controlling the activation of tumor-asso-
ciated macrophages. This study indicates that Myc
inhibition in the microenvironment also has therapeutic
promise, being able to prevent alternative polarization of
macrophages and their pro-tumorigenic behavior [32].
Various considerations follow:
First, since no emergence of resistance to Myc inhibition
was observed in any tumor lesion, these results revealed a
unique, non-adaptive link between tumor and microenvi-
ronment, which provides tremendous therapeutic oppor-
tunities.
Second, it remains to be established whether Myc’s
instruction of the microenvironment is conserved in dif-
ferent tumors and tissues, and downstream of different
oncogenic lesions, or whether the degeneracy observed in
signals upstream of Myc is also maintained in downstream
pathways.
Third, Omomyc exerts an ‘‘edgetic’’ perturbation [33]o f
the Myc transcriptome [29, 34]—that is to say, Omomyc
does not ablate all Myc activities but speciﬁcally Myc-
dependent gene transactivation, rather than transrespres-
sion [29, 34]. This contrasts with approaches designed to
totally ablate the gene product function, such as gene
knockout or RNA interference techniques. Hence, the
microenvironmental effects elicited by Omomyc are criti-
cally dependent on the inhibition of Myc’s transactivated
target genes.
Finally, it is well known that metastasis is a multi-
stage process that requires cancer cells to escape from
the primary tumor, survive in the circulation, seed at
distant sites, and grow. Each of these processes is
inﬂuenced by non-malignant cells of the tumor micro-
environment [35]. It remains to be established whether
Myc is again a critical node during such stages of
tumorigenesis and whether inhibiting Myc has thera-
peutic activity against metastasis.
In summary, instruction of the microenvironment, pre-
viously considered a feature of aberrant, mutated or
overexpressed Myc, is more likely just one of Myc’s many
and diverse physiological cellular activities. This should
come as no surprise if we consider Myc as a nodal, central,
and non-redundant integrator of intracellular and extra-
cellular programs normally involved in organogenesis and
tissue regeneration. It is this same physiological activity
that is hijacked during tumorigenesis, turning Myc from
healing and regenerating saint, to sinner.
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